OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th ...

Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report ...

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...

CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

Cell and gene therapies are currently niche products, even within specialty pharmacy, drugs that, by most definitions, are ...

Increasingly complex cell therapy modalities, including multi-edit knock-in/knockout designs, are accelerating adoption of ...

Learn about the groundbreaking gene therapy for sickle cell disease at Manning Family Children's Hospital in Louisiana, ...

Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.

Mission Bio, the single-cell multi-omics leader, today released data showing that its Targeted Single-Cell DNA+RNA Assay ...

This eBook brings together perspectives from Genetic Engineering News and ElevateBio to examine both the technical and ...